Kyverna Therapeutics, Inc. Common Stock (KYTX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Kyverna Therapeutics, Inc. Common Stock stock (KYTX) is currently trading at $7.64. Analyst consensus price target for KYTX is $29.60. WallStSmart rates KYTX as Sell.
- KYTX PE ratio analysis and historical PE chart
- KYTX PS ratio (Price-to-Sales) history and trend
- KYTX intrinsic value — DCF, Graham Number, EPV models
- KYTX stock price prediction 2025 2026 2027 2028 2029 2030
- KYTX fair value vs current price
- KYTX insider transactions and insider buying
- Is KYTX undervalued or overvalued?
- Kyverna Therapeutics, Inc. Common Stock financial analysis — revenue, earnings, cash flow
- KYTX Piotroski F-Score and Altman Z-Score
- KYTX analyst price target and Smart Rating
Kyverna Therapeutics, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Kyverna Therapeutics, Inc. Common Stock (KYTX) · 4 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity. Significant fundamental concerns warrant caution or avoidance.
Kyverna Therapeutics, Inc. Common Stock (KYTX) Key Strengths (1)
78.22% of shares held by major funds and institutions
Supporting Valuation Data
Kyverna Therapeutics, Inc. Common Stock (KYTX) Areas to Watch (3)
Company is destroying shareholder value
Premium pricing at 3.1x book value
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Kyverna Therapeutics, Inc. Common Stock (KYTX) Detailed Analysis Report
Overall Assessment
This company scores 16/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 1 register as strengths (avg 10.0/10) while 3 fall into concern territory (avg 3.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Price/Book, Market Cap. Some valuation metrics including Price/Book (3.12) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -70.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -70.80% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Book are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
KYTX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
WallStSmart Analysis Synopsis
Data-driven financial summary for Kyverna Therapeutics, Inc. Common Stock (KYTX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Kyverna Therapeutics, Inc. Common Stock operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Debt-to-equity ratio of 0.03 indicates a conservative balance sheet with 34M in cash.
Free cash flow is -44M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 3.35, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Kyverna Therapeutics, Inc. Common Stock.
Bottom Line
Kyverna Therapeutics, Inc. Common Stock offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Kyverna Therapeutics, Inc. Common Stock(KYTX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Kyverna Therapeutics, Inc. is an innovative biotechnology company specializing in the development of advanced immunotherapies for autoimmune diseases and serious medical conditions. Utilizing its cutting-edge genetically engineered T-cell technology, the firm aims to enhance the immune system's capabilities, offering targeted solutions for effective disease management. With a strategic focus on cellular therapies, Kyverna is well-positioned within the biopharmaceutical sector, presenting compelling opportunities for institutional investors looking to support transformative treatments and capitalize on growth in the immunotherapy landscape.